Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time

Health Policy

Volumn 112, Issue 3, 2013, Pages 285-296

  Sandmann, Frank G ^a   Franken, Margreet G ^a   Steenhoek, Adri ^a   Koopmanschap, Marc A ^a  

^a Erasmus University Rotterdam   (Netherlands)

Author keywords

Adalimumab; Drug reimbursement; Evidence development; Imatinib; Pegfilgrastim; Systematic review

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; DASATINIB; ETANERCEPT; HYDROXYUREA; IMATINIB; INFLIXIMAB; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR INHIBITOR;

ANKYLOSING SPONDYLITIS; ARTICLE; BONE MARROW TRANSPLANTATION; BUDGET; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL ASSESSMENT; CONFUSION (UNCERTAINTY); COST UTILITY ANALYSIS; CROHN DISEASE; DERMATOFIBROSARCOMA PROTUBERANS; DRUG DOSE ESCALATION; ECONOMIC EVALUATION; EOSINOPHILIC LEUKEMIA; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPEREOSINOPHILIC SYNDROME; JUVENILE RHEUMATOID ARTHRITIS; LYMPHATIC LEUKEMIA; MEDICAL DECISION MAKING; MIXED MYELODYSPLASTIC MYELOPROLIFERATIVE DISEASE; PRIMARY PREVENTION; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REIMBURSEMENT; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW;

ADALIMUMAB; DRUG REIMBURSEMENT; EVIDENCE DEVELOPMENT; IMATINIB; PEGFILGRASTIM; SYSTEMATIC REVIEW;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BENZAMIDES; DECISION MAKING; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; EVIDENCE-BASED PRACTICE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEALTH EXPENDITURES; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; NETHERLANDS; PIPERAZINES; PYRIMIDINES; RECOMBINANT PROTEINS; REIMBURSEMENT MECHANISMS; UNCERTAINTY;

EID: 84887068322     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2013.03.006     Document Type: Article

References (88)

1. Towse A. Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?. British Journal of Clinical Pharmacology 2010, 70(3):360-366.
2. Klemp M., Frønsdal K.B., Facey K. HTAi Policy Forum. What principles should govern the use of managed entry agreements?. International Journal of Technology Assessment in Health Care 2011, 27(1):77-83.
3. Mrazek M., Mossialos E. Regulating pharmaceutical prices in the European Union. Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality 2004, Open University Press, Maidenhead, UK. E. Mossialos, M. Mrazek, T. Walley (Eds.).
4. Adamski J., Godman B., Ofierska-Sujkowska G., Osinska B., Herholz H., Wendykowska K., et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Services Research 2010, 10:153.
5. Hutton J., Trueman P., Henshall C. Coverage with evidence development: an examination of conceptual and policy issues. International Journal of Technology Assessment in Health Care 2007, 23:425-435.
6. Polain M.le, Franken MG, Koopmanschap MA, Cleemput I. Drug reimbursement systems: international comparison and policy recommendations, (Eds.)(147C). Brussel: Federaal Kenniscentrum voor de gezondheidszorg-Centre federal d'expertise des soins de sante, 2010.
7. Drug Information System of the Health Care Insurance Board (GIPdatabank). Available from [accessed 11.2011]. http://www.gipdatabank.nl/.
8. Minister of Health Conditional inclusion in the pharmaceutical benefit package 2012, Ministry of Health, Welfare and Sport, The Hague, [in Dutch].
9. Schaefer W., Kroneman M., Boerma W., van den Berg M., Westert G., Devillé W., et al. The Netherlands: health system review, health systems in transition. The European Observatory on Health Systems and Policies 2010, 12(1):1-229.
10. College tarieven gezondheidszorg (CTG) Policy guideline I-549. Expensive drugs in hospitals 2002, CTG, Utrecht, [in Dutch].
11. Steenhoek A., Koopmanschap M.A. Considering efficiency of expensive drugs. Medisch Contact 2010, 65(35):1709-1711. [in Dutch].
12. College voor zorgverzekeringen (CVZ) CFH-criteria for assessing therapeutic value 2010, C.V.Z., Diemen, [in Dutch].
13. College voor zorgverzekeringen (CVZ) CFH-report 01/15: Celebrex®, Climodien®, Glivec®, Menopur® 2001, CVZ, Amstelveen, [In Dutch].
14. Dutch State Journal (Staatscourant). Health insurance regulation no. 25074 (2001). Available from [accessed 11.2011]. https://zoek.officielebekendmakingen.nl/.
15. Groot M.T., Ossenkoppele G.J., Kramer M.H.H., van den Boom G., Huijgens P.C., Uyl-de Groot C.A. Drug treatment of chronic myeloid leukemia: a cost effectiveness analysis of first- and second-line treatment. Nederlands Tijdschrift Voor Geneeskunde 2003, 147(30):1460-1465. [in Dutch].
16. Reed S.D., Anstrom K.J., Ludmer J.A., Glendenning G.A., Schulman K.A. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2004, 101(11):2574-2583.
17. Dalziel K., Round A., Stein K., Garside R., Price A. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis. Health Technology Assessment 2004, 8(28 (iii)):1-120.
18. Dalziel K., Round A., Garside R., Stein K. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia. Pharmacoeconomics 2005, 23(5):515-526.
19. Groot M.T., Ossenkoppele G.J., Reed S.D., Huijgens P.C., Uyl-de Groot C.A. Cost-effectiveness in the treatment of chronic myeloid leukaemia with imatinib. Nederlands Tijdschrift voor Hematologie 2006, 3(3):93-103. [in Dutch].
20. Reed S.D., Anstrom K.J., Li Y., Schulman K.A. Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. Pharmacoeconomics 2008, 26(5):435-446.
21. Chen Z., Wang C., Xu X., Feng W. Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP). Value in Health 2009, 12(Suppl. 3):S85-S88.
22. Breitscheidel L. Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia. Journal of Medical Economics 2008, 11(4):571-584.
23. Skrepnek G.H., Ballard E.E. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach. Pharmacotherapy 2005, 25(3):325-334.
24. Gordois A., Scuffham P., Warren E., Ward S. Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia. British Journal of Cancer 2003, 89(4):634-640.
25. Warren E., Ward S., Gordois A., Scuffham P. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase. Clinical Therapeutics 2004, 26(11):1924-1933.
26. Ghatnekar O., Hjalte F., Taylor M. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with chronic myeloid leukemia (CML), resistant to standard dose imatinib: a Swedish model application. Acta Oncologica 2010, 49(6):851-858.
27. Wilson J., Connock M., Song F., Yao G., Fry-Smith A., Raftery J., et al. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. Health Technology Assessment 2005, 9(25):1-142.
28. Huse D.M., von Mehren M., Lenhart G., Joensuu H., Blanke C., Feng W., et al. Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours. Clinical Drug Investigation 2007, 27(2):85-93.
29. Contreras-Hernandez I., Mould-Quevedo J.F., Silva A., Salinas-Escudero G., Villasís-Keever M.A., Granados-García V., et al. A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours. British Journal of Cancer 2008, 98(11):1762-1768.
30. Mabasa V.H., Taylor S.C., Chu C.C., Moravan V., Johnston K., Peacock S., et al. Verification of imatinib cost-effectiveness in advanced gastrointestinal stromal tumor in British Columbia (VINCE-BC study). Journal of Oncology Pharmacy Practice 2008, 14(3):105-112.
31. College voor zorgverzekeringen (CVZ) CFH-report 02/16: Celebrex estradiol/trimegeston (Totelle Cycle®) pegfilgrastim (Neulasta®) 2002, CVZ, Amstelveen, [In Dutch].
32. Dutch State Journal (Staatscourant). Health Insurance Regulation no. 2314 (2003). Available from [accessed 11.2011]. https://zoek.officielebekendmakingen.nl/.
33. Numnum T.M., Kimball K.J., Rocconi R.P., Kilgore L.C., Straughn J.M. Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma-a cost-effectiveness analysis. International Journal of Gynecological Cancer 2007, 17(5):1019-1024.
34. Eldar-Lissai A., Cosler L.E., Culakova E., Lyman G.H. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value in Health 2008, 11(2):172-179.
35. Danova M., Chiroli S., Rosti G., Doan Q.V. Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients. Tumori 2009, 95(2):219-226.
36. Liu Z., Doan Q.V., Malin J., Leonard R. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. Applied Health Economics and Health Policy 2009, 7(3):193-205.
37. Lyman G., Lalla A., Barron R., Dubois R.W. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Current Medical Research and Opinion 2009, 25(2):401-411.
38. Lyman G.H., Lalla A., Barron R.L., Dubois R.W. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. Clinical Therapeutics 2009, 31(5):1092-1104.
39. Ramsey S.D., Liu Z., Boer R., Sullivan S.D., Malin J., Doan Q.V., et al. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value in Health 2009, 12(2):217-225.
40. Sehouli J., Goertz A., Steinle T., Dubois R., Plesnila-Frank C., Lalla A., et al. Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany. Deutsche Medizinische Wochenschrift 2010, 135(9):385-389. [In German].
41. Tan Sean P., Chouaid C., Hettler D., Baud M., Hejblum G., Tilleul P. Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy. Current Medical Research and Opinion 2009, 25(6):1455-1460.
42. European Medicines Agency (EMA) European Public Assessment Report (EPAR) for Humira® (adalimumab) 2011, EMA, London, [last updated on 11.11.2011].
43. College voor zorgverzekeringen (CVZ) CFH-report 03/26: adalimumab (Humira®) 2003, CVZ, Diemen, [In Dutch].
44. Commissie Farmaceutische Hulp (CFH) Adalimumab (Humira®) in psoriatic arthritis 2005, Diemen, CVZ, [in Dutch].
45. College voor zorgverzekeringen (CVZ) Entitlement adalimumab (Humira®), extension of indication 2006, CVZ, Diemen, [in Dutch].
46. College voor zorgverzekeringen (CVZ) Adalimumab (Humira®) for Crohn's disease 2007, CVZ, Diemen, [in Dutch].
47. College voor zorgverzekeringen (CVZ) Adalimumab (Humira®) for plaque psoriasis 2008, CVZ, Diemen, [in Dutch].
48. College voor zorgverzekeringen (CVZ) Adalimumab (Humira®) for polyarticular juvenile idiopathic arthritis 2009, CVZ, Diemen, [in Dutch].
49. Dutch State Journal (Staatscourant). Health Insurance Regulation no. 15 (2004). Available from [accessed 11.2011]. https://zoek.officielebekendmakingen.nl/.
50. Nelson A.A., Pearce D.J., Fleischer A.B., Balkrishnan R., Feldman S.R. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. Journal of the American Academy of Dermatology 2008, 58(1):125-135.
51. Chen Y.F., Jobanputra P., Barton P., Jowett S., Bryan S., Clark W., et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technology Assessment 2006, 10(42):1-229. iii-iv, xi-xiii.
52. Spalding J.R., Hay J. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis. Pharmacoeconomics 2006, 24(12):1221-1232.
53. Bansback N.J., Brennan A., Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Annals of the Rheumatic Diseases 2005, 64(7):995-1002.
54. Hallinen T.A., Soini E.J., Eklund K., Puolakka K. Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting. Rheumatology (Oxford) 2010, 49(4):767-777.
55. Wailoo A.J., Bansback N., Brennan A., Michaud K., Nixon R.M., Wolfe F. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis and Rheumatism 2008, 58(4):939-946.
56. Chiou C.F., Choi J., Reyes C.M. Cost-effectiveness analysis of biological treatments for rheumatoid arthritis. Expert Review of Pharmacoeconomics & Outcomes Research 2004, 4(3):307-315.
57. Malottki K., Barton P., Tsourapas A., Uthman A.O., Liu Z., Routh K., et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technology Assessment 2011, 15(14):1-278.
58. Walsh C.A., Minnock P., Slattery C., Kennedy N., Pang F., Veale D.J., et al. Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007, 46(7):1148-1152.
59. Davies A., Cifaldi M.A., Segurado O.G., Weisman M.H. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. Journal of Rheumatology 2009, 36(1):16-26.
60. Brennan A., Bansback N., Nixon R., Madan J., Harrison M., Watson K., et al. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford) 2007, 46(8):1345-1354.
61. Kielhorn A., Porter D., Diamantopoulos A., Lewis G. UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug. Current Medical Research and Opinion 2008, 24(9):2639-2650.
62. Sizto S., Bansback N., Feldman S.R., Willian M.K., Anis A.H. Economic evaluation of systemic therapies for moderate to severe psoriasis. British Journal of Dermatology 2009, 160(6):1264-1272.
63. Knight C., Mauskopf J., Ekelund M., Singh A., Yang S., Boggs R. Cost-effectiveness of treatment with etanercept for psoriasis in Sweden. The European Journal of Health Economics 2011, [Epub ahead of print].
64. Greiner R.A., Braathen L.R. Cost-effectiveness of biologics for moderate-to-severe psoriasis from the perspective of the Swiss healthcare system. European Journal of Dermatology 2009, 19(5):494-499.
65. Schmitt-Rau K., Rosenbach T., Radtke M.A., Augustin M. Cost-effectiveness of biological therapy in remission induction of moderate to severe plaque psoriasis. Dermatology 2010, 221(3):236-242.
66. Anis A.H., Bansback N., Sizto S., Gupta S.R., Willian M.K., Feldman S.R. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. Journal of Dermatological Treatment 2011, 22(2):65-74.
67. de Portu S., Del Giglio M., Altomare G., Arcangeli F., Berardesca E., Calzavara-Pinton P., et al. Cost-effectiveness analysis of TNF-alpha blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system. Dermatology and Therapy 2010, 23(Suppl. 1):S7-S13.
68. Bodger K., Kikuchi T., Hughes D. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Alimentary Pharmacology and Therapeutics 2009, 30(3):265-274.
69. Loftus E.V., Johnson S.J., Yu A.P., Wu E.Q., Chao J., Mulani P.M. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease. European Journal of Gastroenterology and Hepatology 2009, 21(11):1302-1309.
70. Dretzke J., Edlin R., Round J., Connock M., Hulme C., Czeczot J., et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease. Health Technology Assessment 2011, 15(6):1-244.
71. Yu A.P., Johnson S., Wang S.T., Atanasov P., Tang J., Wu E., et al. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease. Pharmacoeconomics 2009, 27(7):609-621.
72. Kaplan G.G., Hur C., Korzenik J., Sands B.E. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Alimentary Pharmacology and Therapeutics 2007, 26(11-12):1509-1520.
73. Cummins E., Asseburg C., Prasad M., Shore E., Morris J., Briggs A., et al. Cost effectiveness of golimumab for the treatment of active psoriatic arthritis. The European Journal of Health Economics 2011, [Epub ahead of print].
74. Rodgers M., Epstein D., Bojke L., Yang H., Craig D., Fonseca T., et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technology Assessment 2011, 15(10):1-329. i-xxi.
75. Botteman M.F., Hay J.W., Luo M.P., Curry A.S., Wong R.L., van Hout B.A. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom. Rheumatology (Oxford) 2007, 46(8):1320-1328.
76. Ungar W.J., Costa V., Hancock-Howard R., Feldman B.M., Laxer R.M. Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs. Arthritis Care and Research 2011, 63(1):111-119.
77. Xie F., Blackhouse G., Assasi N., Gaebel K., Robertson D., Goeree R. Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost Effectiveness and Resource Allocation 2009, 7:20.
78. Daniels N., Sabin J. Limits to health care: fair procedures, democratic deliberation, and the legitimacy problem for insurers. Philosophy and Public Affairs 1997, 26(4):303-350.
79. Grandfils N. Drug price setting and regulation in France. Paris: IRDES Institute for Research and Information in Health Economics. 2008. Report No.: Working Papers DT 16.
80. Van Ganse E., Chamba G., Bruet G., Becquart V., Stamm C., Lopes S., et al. PPRI Pharma Profile France 2008. Pharmaceutical Pricing and Reimbursement Information; Commissioned by the European Commission, Directorate-General Health and Consumer Protection and Austrian Federal Ministry of Health, Family and Youth. WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. Gesundheit Österreich GmbH.
81. Sermet C., Andrieu V., Godman B., Van Ganse E., Haycox A., Reynier J.P. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. Applied Health Economics and Health Policy 2010, 8:7-24.
82. TLV Hypertension: a review of medicines for lowering blood pressure 2008, The Dental and Pharmaceutical Benefits Agency, Solna.
83. Friedberg M., Saffran B., Stinson T.J., Nelson W., Bennett C.L. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. Journal of the American Medical Association 1999, 282(15):1453-1457.
84. Miners A.H., Garau M., Fidan D., Fischer A.J. Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study. British Medical Journal 2005, 330:65.
85. Bell C.M., Urbach D.R., Ray J.G., Bayoumi A., Rosen A.B., Greenberg D., et al. Bias in published cost effectiveness studies: systematic review. British Medical Journal 2006, 332(7543):699-703.
86. Drummond M.F., Pang F. Transferability of economic evaluation results. Economic evaluation of health care: merging theory with practice 2001, Oxford University Press, Oxford. M.F. Drummond, A.L. McGuire (Eds.).
87. Welte R., Feenstra T., Jager H., Leidl R. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 2004, 22(13):857-876.
88. Drummond M., Barbieri M., Cook J., Glick H.A., Lis J., Malik F., et al. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value in Health 2009, 12(4):409-418.